Every 8-K that Bio Rad Labs Inc (BIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIO filings page.
Bio-Rad Laboratories reported second-quarter 2026 results and outlined a restructuring plan. Net sales were $651.0 million, essentially flat versus the prior year. GAAP net income was $371.4 million, or $13.85 per diluted share, with results substantially contributed to by a gain from the change in fair value of its Sartorius AG investment. Non-GAAP net income was $70.2 million, or $2.62 per diluted share, roughly in line with 2025.
Operating cash flow was $98.7 million and free cash flow was $66.7 million; the company repurchased approximately $32 million of shares. Life Science revenue declined while Clinical Diagnostics grew modestly. Bio-Rad initiated a strategy-driven global restructuring including headcount reductions, functional consolidation, and facility closures, and expects total pre-tax charges of approximately $80–$90 million, primarily for one-time termination benefits, with substantial completion expected by the end of fiscal 2027. Management reaffirmed full-year 2026 guidance for non-GAAP currency-neutral revenue between about a 3.0% decline and 0.5% growth and a non-GAAP operating margin of roughly 10.0–12.0%.
Bio-Rad Laboratories reported first-quarter 2026 net sales of $592.1 million, up 1.1% year over year, but down 4.2% on a currency-neutral basis as both Life Science and Clinical Diagnostics segments faced softer demand.
The company recorded a large GAAP net loss of $527.1 million, or $(19.55) per diluted share, mainly from a $738.2 million loss on the change in fair value of equity securities, including its Sartorius AG investment. On a non-GAAP basis, net income was $50.9 million, or $1.89 per diluted share, down from $2.54 a year earlier, reflecting lower margins and higher adjustments.
Operating cash flow was $108.1 million and free cash flow $78.1 million, both below the prior year, although management highlighted strong cash generation and share repurchases of about 176 thousand shares. Bio-Rad also lowered its full-year 2026 outlook, now expecting non-GAAP currency-neutral revenue between a 3.0% decline and 0.5% growth and a non-GAAP operating margin of roughly 10.0% to 12.0%, down from its prior 12.0% to 12.5% margin range.
Bio-Rad Laboratories reported results of its April 21, 2026 annual meeting. Stockholders approved an amended 2017 Incentive Award Plan that increases the shares of common stock reserved for issuance by 335,000 and extends the plan’s expiration to March 18, 2036.
All nominated directors were elected by the required majorities, KPMG LLP was ratified as independent auditor for the year ending December 31, 2026, and executive compensation received majority support in a non-binding advisory vote. A stockholder proposal regarding the company’s dual class capital structure did not receive the required majority approval.
Bio-Rad Laboratories, Inc. filed an update on its investment in Sartorius AG, sharing Sartorius’ latest full-year 2025 financial figures that Sartorius disclosed on February 16, 2026. The data come directly from Sartorius’ audited consolidated financial statements prepared under IFRS.
For the year ended December 31, 2025, Sartorius reported sales revenue of €3,538.1 million, gross profit of €1,636.7 million, earnings before interest and taxes (EBIT) of €542.6 million and net profit of €230.4 million. Cash flow from operating activities was €837.0 million, while cash flows from investing and financing activities were negative €513.7 million and €591.4 million, respectively. As of December 31, 2025, Sartorius reported current assets of €1,766.2 million, non-current assets of €7,951.1 million, current liabilities of €1,967.4 million, non-current liabilities of €3,882.6 million and equity of €3,867.2 million.
Bio-Rad Laboratories reported fourth-quarter and full-year 2025 results showing modest revenue growth but pressured margins. Q4 2025 revenue was $693.2 million, up 3.9% year over year, while full-year revenue reached $2,583.2 million, up 0.7% and essentially flat on a currency-neutral basis.
GAAP gross margin declined to 49.8% in Q4 and 51.9% for 2025, reflecting about $13 million of product rationalization write-offs and a $172.8 million impairment tied to discontinuation and reprioritization of R&D programs, which drove a Q4 GAAP operating loss of $118.9 million.
Despite weaker operating margins, GAAP net income swung sharply positive to $720.0 million in Q4 and $759.9 million for 2025, largely from gains on the Sartorius AG investment. On a non-GAAP basis, Q4 net income was $67.7 million, or $2.51 per diluted share, and full-year non-GAAP net income was $270.5 million, or $9.92 per diluted share, both slightly below 2024 levels.
Free cash flow was strong at $374.6 million for 2025, supported by $532.2 million in operating cash flow. Management highlighted solid Clinical Diagnostics growth, continued headwinds in Life Science from constrained academic and biotech funding, successful integration of the Stilla Technologies acquisition, and share repurchases of $296 million.
For full-year 2026, Bio-Rad targets non-GAAP, currency-neutral revenue growth of approximately 0.5% to 1.5%, non-GAAP operating margin of about 12.0% to 12.5%, non-GAAP gross margin of 54.0% to 54.5%, and free cash flow between $375 million and $395 million.
Bio-Rad Laboratories (BIO) announced financial results for the quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 and a Supplemental Earnings Presentation as Exhibit 99.2, which are also available on its website in Investor Relations under “Events & Presentations.” Under General Instruction B.2, these materials are furnished, not filed, are not subject to Section 18 of the Exchange Act, and are not incorporated by reference except by specific reference.
Bio-Rad Laboratories, Inc. reported the passing of its co-founder and Director Emeritus, Alice N. Schwartz, under a Regulation FD disclosure. The company announced that she died on September 25, 2025, at the age of 99. This reflects a significant moment in the company’s history given her foundational role, but the disclosure does not describe any immediate operational or financial impacts.
The announcement was made on September 29, 2025, and a related press release was provided as an exhibit to the report. The company states that this information is being furnished, not filed, which limits how it is treated under securities law liability provisions.
Bio-Rad Laboratories, Inc. filed a report describing an informational investor webinar focused on its Droplet Digital™ PCR (ddPCR™) product portfolio held on August 26, 2025. The webinar included a presentation and Q&A session with President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju. A live webcast and a replay, along with the slide presentation, are or will be available for up to a year in the Investor Relations section of the company’s website under “Events & Presentations.” The slide deck for the webinar is also provided as Exhibit 99.1, with the disclosure treated as furnished under Regulation FD rather than filed for liability purposes.